DSpace Repository

Assessment and management of asymptomatic COVID-19 infection: A systematic review

Show simple item record

dc.contributor.author Barboza, Joshuan J.
dc.contributor.author Chambergo-Michilot, Diego
dc.contributor.author Velasquez-Sotomayor, Mariana
dc.contributor.author Silva-Rengifo, Christian
dc.contributor.author Diaz-Arocutipa, Carlos
dc.contributor.author Caballero-Alvarado, Jose
dc.contributor.author Garcia-Solorzano, Franko O.
dc.contributor.author Alarcon-Ruiz, Christoper A.
dc.contributor.author Albitres Flores, Julio Leonardo Rafael
dc.contributor.author Málaga Rodríguez, Germán Javier
dc.contributor.author Schlagenhauf, Patricia
dc.contributor.author Rodriguez-Morales, Alfonso J.
dc.date.accessioned 2021-05-18T21:44:14Z
dc.date.available 2021-05-18T21:44:14Z
dc.date.issued 2021
dc.identifier.uri https://hdl.handle.net/20.500.12866/9354
dc.description.abstract BACKGROUND: COVID-19 can be asymptomatic in a substantial proportion of patients. The assessment and management of these patients constitute a key element to stop dissemination. AIM: To describe the assessment and treatment of asymptomatic infection in patients with a confirmed diagnosis of COVID-19. METHODS: We searched five databases and search engines for preprints/preproofs, up to August 22, 2020. We included cohort, cross-sectional, and case series studies, reporting the assessment and management of asymptomatic individuals. We extracted data on total discharges with negative PCR, length of hospitalization, treatment, and number of patients who remained asymptomatic. A random-effects model with inverse variance method was used to calculate the pooled prevalence. RESULTS: 41 studies (nine cross-sectional studies, five retrospective studies and 27 reports/case series; 647 asymptomatic individuals), were included, of which 47% were male (233/501). The age of patients was between 1month and 73 years. In patients who became symptomatic, length of hospitalization mean was 13.6 days (SD 6.4). Studies used lopinavir/ritonavir, hydroxychloroquine plus ritonavir/lopinavir, hydroxychloroquine with and without azithromycin, ribavirin plus interferon and interferon alfa. The proportion of individuals who remained asymptomatic was 91% (463/588 patients; 95%CI: 78.3%-98.7%); and asymptomatic individuals discharged with negative PCR was 86% (102/124 individuals; 95%CI: 58.4%-100%). CONCLUSIONS: There is no standard treatment for asymptomatic COVID-19 individuals. There are no studies of adequate design to make this decision. It has been shown that most asymptomatic individuals who were followed have recovered, but this cannot be attributed to standard treatment en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Travel Medicine and Infectious Disease
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject COVID-19 en_US
dc.subject SARS-CoV-2 en_US
dc.subject Systematic review en_US
dc.subject Asymptomatic en_US
dc.title Assessment and management of asymptomatic COVID-19 infection: A systematic review en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1016/j.tmaid.2021.102058
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn 1873-0442


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics